Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-37515
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 4F8H6
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Purified recombinant fragment of human Fas/TNFRSF6/CD95 expressed in E. Coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Theoretical MW
37.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free
Western Blot: Fas/TNFRSF6/CD95 Antibody (4F8H6)BSA Free [NBP2-37515]
Western Blot: Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free [NBP2-37515] - Western blot analysis using Fas/TNFRSF6/CD95 mouse monoclonal antibody against Hela (1), Jurkat (2) cell lysate.Immunocytochemistry/ Immunofluorescence: Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free [NBP2-37515]
Immunocytochemistry/Immunofluorescence: Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free [NBP2-37515] - Immunofluorescence analysis of Hela cells using Fas/TNFRSF6/CD95 mouse monoclonal antibody (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.Flow Cytometry: Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free [NBP2-37515]
Flow Cytometry: Fas Receptor/TNFRSF6/CD95 Antibody (4F8H6) [NBP2-37515] - An intracellular stain was performed on HeLa cells with Fas/TNFRSF6/CD95 Antibody (4F8H6) NBP2-37515R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 550.Applications for Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free
Application
Recommended Usage
ELISA
1:10000
Flow Cytometry
1:200 - 1:400
Immunocytochemistry/ Immunofluorescence
1:200 - 1:1000
Western Blot
1:500 - 1:2000
Application Notes
This antibody is Cytof ready.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Format
BSA Free
Preservative
0.05% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Fas/TNFRSF6/CD95
Fas-FasL-mediated apoptosis is important in immune homeostasis and removal of autoreactive T cells, autoreactive B cells, cytotoxic natural killer (NK) cells, and more (1,2,7). Dysfunction and mutations in the Fas receptor and the Fas-FasL signaling axis is associated a loss of apoptotic signaling and removal of autoreactive cells, which correlates with several autoimmune diseases including systemic lupus erythematosus (SLE), autoimmune lymphoproliferative syndrome (ALPS), and multiple sclerosis (MS) (1-4,6,7). In addition to apoptosis and cell death signaling, FasL/TNFRSF6/CD95 mediates other pathways involved in proliferation, survival, and differentiation (3,4,6,8). More specifically, Fas has been shown to activate the NF-kappaB pathway, driving innate immunity which includes IL-1beta production and functioning in host defense (3,4,6,8). Fas is also involved in adaptive immunity playing a role in co-stimulation of CD4+ and CD8+ T cell activation as well as precocious differentiation of naive cells to effector memory T cells (3,4,6). Differentiation into effector memory T cells shows protection against autoimmunity but also limits antitumor response to a form of cancer immunotherapy called adoptive cell transfer (ACT) (3,4). The non-apoptotic roles of the Fas/TNFRSF6/CD95 receptor highlight its potential as a target for both treating autoimmune diseases and in cancer immunotherapy (3,4).
References
1. Singh R, Pradhan V, Patwardhan M, Ghosh K. APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases. Indian J Hum Genet. 2009;15(3):98-102. https://doi.org/10.4103/0971-6866.60184
2. Magerus A, Bercher-Brayer C, Rieux-Laucat F. The genetic landscape of the FAS pathway deficiencies. Biomed J. 2021;44(4):388-399. https://doi.org/1010.1016/j.bj.2021.06.005
3. Guegan JP, Legembre P. Nonapoptotic functions of Fas/CD95 in the immune response. FEBS J. 2018;285(5):809-827. https://doi.org/10.1111/febs.14292
4. Yi F, Frazzette N, Cruz AC, Klebanoff CA, Siegel RM. Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy. Trends Mol Med. 2018;24(7):642-653. https://doi.org/10.1016/j.molmed.2018.05.004
5. Uniprot (P25445)
6. Guegan JP, Ginestier C, Charafe-Jauffret E, et al. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Semin Cancer Biol. 2020;60:121-131. https://doi.org/10.1016/j.semcancer.2019.06.004
7. Volpe E, Sambucci M, Battistini L, Borsellino G. Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis. Front Immunol. 2016;7:382. Published 2016 Sep 27. https://doi.org/10.3389/fimmu.2016.00382
8. Cullen SP, Martin SJ. Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer. Semin Cell Dev Biol. 2015;39:26-34. https://doi.org/10.1016/j.semcdb.2015.01.012
Long Name
Fibroblast-associated
Alternate Names
Apo-1, APT1, CD95, TNFRSF6
Gene Symbol
FAS
Additional Fas/TNFRSF6/CD95 Products
Product Documents for Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free
Product Specific Notices for Fas/TNFRSF6/CD95 Antibody (4F8H6) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...